WINNIPEG, Manitoba – January 5, 2016 – Kane Biotech Inc. (TSX-V:KNE) (the “Corporation”) a biotechnology company developing and commercializing products that prevent and remove microbial biofilms is pleased to appoint Audrey Goertzen CPA, CGA as Kane Biotech’s new Chief Financial Officer (CFO) replacing Mark Matthewson CPA, CA, effective January 4, 2016. Ms. Goertzen has broad experience in financial management and accounting over the past 22 years in public accounting, public and government crown corporations, as well as rapidly growing entrepreneurial companies. Mr. Matthewson's services had been provided to Kane Biotech through a Management Services Agreement with MKM Management Services Ltd.
“The board and management team welcomes Audrey to Kane Biotech as CFO and thanks Mark Matthewson and Christine Johnson for their valuable contribution and excellent financial skills provided to Kane over the past four years”, stated Mark Ahrens-Townsend, President and Chief Executive Officer.
Commercialization Team Expansion
The Corporation is pleased to announce the following personnel who have joined the Kane Biotech team over the past few months to focus on the commercialization of Kane Biotech’s expansive patented and patent protected anti-biofilm technology:
- Wendy Nachtigall – Director, Retail
- Erika Linden – Marketing Manager
- Avery-Anne Gervais – Retail Accounts Associate
- Andrea Gordon – Director, Regulatory and Quality Assurance
- Courtney Dalton – Supply Chain Manager
- Diane Gordon Pappas – Research Associate
- Each brings a wealth of experience as well as new creativity, innovation, and energy to Kane Biotech as it develops and launches new products into new markets.
U.S. Sales Representation Agreement
Kane Biotech is excited to announce it has entered into a Sales Representation Agreement with a U.S. based marketing, consulting, and sales management firm specializing in the pet industry. Work has already started with Kane’s commercialization team to launch the Corporation’s bluestemTM pet oral care brand into the United States in Q1 2016. More information about bluestemTM can be found at www.bluestempets.com.
The Corporation has granted an aggregate of 2,825,000 stock options at an exercise price of $0.08 per common share to Kane Biotech’s new employees and an advisor to management and the board. The options fully vest over a two-year period, are set to expire five years from the date of grant, and are subject to TSX Venture Exchange acceptance and the terms of Kane Biotech’s stock option plan. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise of such options will be subject to resale restriction for a period of four months from the date of the grant.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as tooth decay, medical device associated infections and recurrent urinary tract infections.
Kane Biotech uses patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several health, medical and industrial applications.